Helen J. Blair

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

Lani F. Wu, S. Altschuler, T. Haferlach, 2023 .

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

A. Moorman, H. Bell, Martin Galler, 2024, Leukemia.

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

O. Heidenreich, H. Blair, J. Vormoor, 2013, Leukemia.

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth

Salam A. Assi, C. Bonifer, P. Cockerill, 2024, Nature communications.

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth

Salam A. Assi, C. Bonifer, P. Cockerill, 2023, Cell reports.